Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA 4359

Next Previous
Drug Profile

mRNA 4359

Alternative Names: Checkpoint cancer vaccine - Moderna Therapeutics; mRNA-4359

Latest Information Update: 16 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma; Solid tumours

Most Recent Events

  • 22 Apr 2026 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Poland, Germany (IM), prior to April 2026 (NCT05533697)
  • 22 Apr 2026 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany, Poland (IM), prior to April 2026 (NCT05533697)
  • 22 Apr 2026 Phase-I/II clinical trials in Malignant melanoma (First-line therapy, Late-stage disease, Metastatic disease, Monotherapy) in Poland, Germany (IM), prior to April 2026 (NCT05533697)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top